{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T10:51:53Z","timestamp":1772275913479,"version":"3.50.1"},"reference-count":14,"publisher":"Tohoku University Medical Press","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2012]]},"DOI":"10.1620\/tjem.228.295","type":"journal-article","created":{"date-parts":[[2012,10,26]],"date-time":"2012-10-26T23:27:55Z","timestamp":1351294075000},"page":"295-299","source":"Crossref","is-referenced-by-count":17,"title":["Splenic Irradiation as a Component of a Reduced-Intensity Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Myelofibrosis with Massive Splenomegaly"],"prefix":"10.1620","volume":"228","author":[{"given":"Takeshi","family":"Ito","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Akagi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadakazu","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kawabata","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Ichinohe","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akifumi","family":"Takaori-Kondo","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"622","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Bacigalupo, A., Soraru, M., Dominietto, A., Pozzi, S., Geroldi, S., Van Lint, M.T., Ibatici, A., Raiola, A.M., Frassoni, F., De Stefano, F., Verdiani, S., Casarino, L. &amp; Barosi, G. (2010) Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. <i>Bone Marrow Transplant<\/i>., <b>45<\/b>, 458-463.","DOI":"10.1038\/bmt.2009.188"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Ballen, K.K., Shrestha, S., Sobocinski, K.A., Zhang, M.J., Bashey, A., Bolwell, B.J., Cervantes, F., Devine, S.M., Gale, R.P., Gupta, V., Hahn, T.E., Hogan, W.J., Kroger, N., Litzow, M.R., Marks, D.I., Maziarz, R.T., McCarthy, P.L., Schiller, G., Schouten, H.C., Roy, V., Wiernik, P.H., Horowitz, M.M., Giralt, S.A. &amp; Arora, M. (2010) Outcome of transplantation for myelofibrosis. <i>Biol. Blood Marrow Transplant<\/i>., <b>16<\/b>, 358-367.","DOI":"10.1016\/j.bbmt.2009.10.025"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Bouabdallah, R., Coso, D., Gonzague-Casabianca, L., Alzieu, C., Resbeut, M. &amp; Gastaut, J.A. (2000) Safety and efficacy of splenic irradiation in the treatment of patients with idiopathic myelofibrosis: a report on 15 patients. <i>Leuk. Res<\/i>., <b>24<\/b>, 491-495.","DOI":"10.1016\/S0145-2126(00)00018-7"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Cervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J.T., Morra, E., Vannucchi, A.M., Mesa, R.A., Demory, J.L., Barosi, G., Rumi, E. &amp; Tefferi, A. (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. <i>Blood<\/i>, <b>113<\/b>, 2895-2901.","DOI":"10.1182\/blood-2008-07-170449"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Elliott, M.A., Chen, M.G., Silverstein, M.N. &amp; Tefferi, A. (1998) Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. <i>Br. J. Haematol<\/i>., <b>103<\/b>, 505-511.","DOI":"10.1046\/j.1365-2141.1998.00998.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Gratwohl, A., Hermans, J., van Biezen, A., Arcese, W., Debusscher, L., Ernst, P., Ferrant, A., Frassoni, F., Gahrton, G., Iriondo, A., Kolb, H.J., Link, H., Niederwieser, D., Ruutu, T., Siegert, W. &amp; Zwaan, F.E. (1996) Splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia. Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). <i>Br. J. Haematol<\/i>., <b>95<\/b>, 494-500.","DOI":"10.1046\/j.1365-2141.1996.d01-1929.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Harrison, C., Kiladjian, J.J., Al-Ali, H.K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D.S., Levy, R., Knoops, L., Cervantes, F., Vannucchi, A.M., Barbui, T. &amp; Barosi, G. (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. <i>N. Engl. J. Med<\/i>., <b>366<\/b>, 787-798.","DOI":"10.1056\/NEJMoa1110556"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Jabro, G., Koc, Y., Boyle, T., Schenkein, D.P., Ravalese, J., Wazer, D. &amp; Miller, K.B. (1999) Role of splenic irradiation in patients with chronic myeloid leukemia undergoing allogeneic bone marrow transplantation. <i>Biol. Blood Marrow Transplant<\/i>., <b>5<\/b>, 173-179.","DOI":"10.1053\/bbmt.1999.v5.pm10392963"},{"key":"9","unstructured":"Kr&ouml;ger, N., Holler, E., Kobbe, G., Bornhauser, M., Schwerdtfeger, R., Baurmann, H., Nagler, A., Bethge, W., Stelljes, M., Uharek, L., Wandt, H., Burchert, A., Corradini, P., Schubert, J., Kaufmann, M., Dreger, P., Wulf, G.G., Einsele, H., Zabelina, T., Kvasnicka, H.M., Thiele, J., Brand, R., Zander, A.R., Niederwieser, D. &amp; de Witte, T.M. (2009) Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Blood<\/i>, <b>114<\/b>, 5264-5270."},{"key":"10","doi-asserted-by":"crossref","unstructured":"Patriarca, F., Bacigalupo, A., Sperotto, A., Isola, M., Soldano, F., Bruno, B., van Lint, M.T., Iori, A.P., Santarone, S., Porretto, F., Pioltelli, P., Visani, G., Iacopino, P., Fanin, R. &amp; Bosi, A. (2008) Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Haematologica<\/i>, <b>93<\/b>, 1514-1522.","DOI":"10.3324\/haematol.12828"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Robin, M., Tabrizi, R., Mohty, M., Furst, S., Michallet, M., Bay, J.O., Cahn, J.Y., De Coninck, E., Dhedin, N., Bernard, M., Rio, B., Buzyn, A., Huynh, A., Bilger, K., Bordigoni, P., Contentin, N., Porcher, R., Socie, G. &amp; Milpied, N. (2011) Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). <i>Br. J. Haematol<\/i>., <b>152<\/b>, 331-339.","DOI":"10.1111\/j.1365-2141.2010.08417.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Stewart, W.A., Pearce, R., Kirkland, K.E., Bloor, A., Thomson, K., Apperley, J., McQuaker, G., Marks, D.I., Craddock, C., McCann, S., Russell, N., Cook, G. &amp; Kottaridis, P.D. (2010) The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study. <i>Bone Marrow Transplant<\/i>., <b>45<\/b>, 1587-1593.","DOI":"10.1038\/bmt.2010.14"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Tefferi, A., Mesa, R.A., Nagorney, D.M., Schroeder, G. &amp; Silverstein, M.N. (2000) Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. <i>Blood<\/i>, <b>95<\/b>, 2226-2233.","DOI":"10.1182\/blood.V95.7.2226"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Verstovsek, S., Mesa, R.A., Gotlib, J., Levy, R.S., Gupta, V., DiPersio, J.F., Catalano, J.V., Deininger, M., Miller, C., Silver, R.T., Talpaz, M., Winton, E.F., Harvey, J.H. Jr., Arcasoy, M.O., Hexner, E., Lyons, R.M., Paquette, R., Raza, A., Vaddi, K., Erickson-Viitanen, S., Koumenis, I.L., Sun, W., Sandor, V. &amp; Kantarjian, H.M. (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. <i>N. Engl. J. Med<\/i>., <b>366<\/b>, 799-807.","DOI":"10.1056\/NEJMoa1110557"}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/228\/4\/228_295\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T19:50:14Z","timestamp":1619639414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/228\/4\/228_295\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.228.295","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}